| Line Item | 2024-03-31 | Y/Y |
|---|---|---|
| Revenue | $0 | — |
| R&D Expense | $2.2M | +198.7% |
| SG&A Expense | $5.2M | +321.6% |
| Operating Income | -$12.0M | -504.5% |
| Pre-tax Income | -$15.4M | -675.2% |
| Income Tax | $0 | — |
| Net Income | -$15.4M | -675.2% |
| EPS (Basic) | -$1.05 | -517.6% |
| Line Item | 2024-03-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $8.6M | +895.1% |
| Current Assets | $9.4M | +985.7% |
| Total Assets | $9.4M | +987.5% |
| Current Liabilities | $777K | +251.6% |
| Total Liabilities | $1.8M | +705.0% |
| Stockholders' Equity | $7.6M | +1084.5% |
| Line Item | 2024-03-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$6.6M | -258.6% |
| Capital Expenditures | $19K | — |
| Investing Cash Flow | -$19K | — |
| Financing Cash Flow | $14.4M | +2034.8% |
| Free Cash Flow | -$6.7M | -259.6% |